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The causative agent of Severe Acute Respiratory Syndrome (SARS) has been identified as a new type of coronavirus. Here we have examined the ability of adenoviral gene transfer of codon-optimized SARS-CoV strain Urbani structural antigens spike (S) protein S1 fragment, membrane protein (M), and nucleocapsid protein (N) to induce broad immunity in the non-human primate. Six rhesus macaques were immunized intramuscularly with a combination of the three Ad5-SARS-CoV vectors and boosted on day 28. The vaccinated animals all had antibody responses against S1 and T-cell responses against the antigens. Importantly, all six vaccinated animals showed strong neutralizing antibody responses to SARS-CoV infection in vitro. These results demonstrate that an adenoviral-based vaccine can induce strong SARS-CoV-specific immune responses in the monkey, and hold promise for development of a protective vaccine against the SARS etiologic agent.
